An Open-label, Randomized, Single and Multiple Dosing Phase I Clinical Trial to Evaluate Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 After Oral Administration in Healthy Korean and Caucasian Male Subjects
Latest Information Update: 07 Jul 2022
At a glance
- Drugs IN-C005 (Primary)
- Indications Gastro-oesophageal reflux
- Focus Pharmacokinetics
- Sponsors HK inno.N
- 05 Nov 2020 Status changed from not yet recruiting to recruiting.
- 30 Jul 2020 New trial record